Sosei Heptares enters agreement with Twist Bioscience

By The Science Advisory Board staff writers

December 20, 2021 -- Twist Bioscience and Sosei Group have formed a strategic collaboration to discover therapeutic antibodies against G protein-coupled receptors (GPCR) identified by Sosei Heptares.

The collaboration will utilize Sosei Heptares' GPCR target proteins, which have been isolated and stabilized using the company's stabilized receptor platform. Twist will leverage its antibody libraries, including two synthetic GPCR-focused antibody libraries, and apply its bioinformatics approaches.

Sosei Heptares will hold exclusive, full global rights to develop and commercialize any antibody leads identified and directed to the targets of interest. Twist will be eligible for an upfront payment, ongoing R&D costs, and future payments based on the achievement of predefined development milestones, the companies said.

No financial terms of the agreement were disclosed.


Copyright © 2021 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here